Thymalfasin
Also known as: TA1, Thymosin alpha-1, Thymosin alpha‑1, Thymosin α1, Tα1, Zadaxin
Source Thymalfasin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Thymalfasin (thymosin‑α1) is a synthetic immunomodulatory peptide approved as a prescription drug. Delivered by subcutaneous injection, it is used as an immune‑enhancing adjuvant in chronic viral hepatitis, hepatocellular carcinoma, and selected solid‑tumour settings. The peptide seeks to strengthen Th1‑type cellular immunity, promote T‑cell maturation, and augment antiviral or antitumour responses when combined with standard therapies.
Mechanism of Action
Thymalfasin binds to immune cells and shifts the immune balance toward a Th1 phenotype. It promotes differentiation and maturation of T cells, enhances natural‑killer cell activity, and stimulates dendritic‑cell function. In viral hepatitis models it also displays a direct antiviral effect, likely through interferon‑related pathways. The net result is heightened cellular immunity that can improve clearance of infected cells and support antitumour immune surveillance.
What the Research Shows
Pre‑clinical work showed thymalfasin restores immune function in thymectomised animals and reduces tumour growth in mouse melanoma and rat colorectal cancer models. Early clinical pilots reported 70% sustained virologic response when combined with interferon‑based regimens for chronic hepatitis B and improved response rates in hepatitis C, although a later phase‑III trial in HCV non‑responders failed to raise SVR but lowered relapse. A randomized trial of 400 colorectal‑cancer patients receiving peri‑operative thymalfasin (1.6 mg twice or thrice weekly) demonstrated lower infection rates, reduced recurrence and metastasis, and longer disease‑free survival. A phase‑II neoadjuvant study in locally advanced gastric cancer combined thymalfasin with anti‑PD‑1 and chemotherapy, achieving a 30% pathological complete response and acceptable safety. An ongoing protocol plans a large multicentre trial of thymalfasin as adjuvant therapy after curative resection of HBV‑related hepatocellular carcinoma.
Reported Benefits
Clinical data suggest thymalfasin can boost immune parameters, leading to fewer peri‑operative infections and lower tumour recurrence in colorectal cancer, and higher disease‑free survival. In hepatitis B and C, it may improve sustained virologic response when added to standard antiviral regimens, and reduce relapse after therapy. Early cancer trials report enhanced pathological response and nodal clearance in gastric adenocarcinoma, indicating potential to augment antitumour immunity.
Limitations of the Evidence
Most evidence comes from pilot or single‑centre studies; large, definitive phase‑III trials are lacking for most indications. The HCV phase‑III trial did not improve primary virologic outcomes, highlighting inconsistent antiviral benefit. Safety data are limited to relatively small cohorts, and the ongoing HCC trial remains unpublished. Consequently, the overall strength of evidence varies, and broader clinical adoption awaits confirmatory trials.
Safety Considerations
Thymalfasin is generally well tolerated, with most reports describing mild injection‑site reactions. In the gastric cancer phase‑II trial, 93% of patients experienced any‑grade adverse events, 26% had grade ≥ 3 events, and 23% reported immune‑related events, underscoring the need for monitoring. The colorectal‑cancer study noted reduced peri‑operative infections, suggesting a favorable safety profile in surgical settings. Caution is advised in patients with autoimmune disorders or severe immunosuppression.
How It Is Administered
The peptide is supplied for subcutaneous injection. Clinical protocols have used 1.6 mg administered twice weekly (standard dose) or thrice weekly (high dose) for periods ranging from several weeks to a year, depending on the indication (e.g., peri‑operative adjuvant, neoadjuvant, or chronic hepatitis adjunct). No oral formulations are reported.
Routes of Administration
Goals & Uses
- Chronic Hepatitis C treatmentAntiviralHigh
- Support cancer immunotherapyOncologyLow
- Chronic Hepatitis B treatmentAntiviralHigh
- Sepsis adjunctive therapyCritical Care / ImmunomodulationModerate
- Cancer immunoadjuvantOncologyModerate
- Immune reconstitution in immunocompromised patientsImmunomodulationModerate
- Enhance antiviral immunityViral InfectionModerate
- Treat immunodeficiencyImmune DeficiencyModerate
- COVID-19 adjunctive treatmentAntiviral / ImmunomodulationLow
Contraindications
- Hypersensitivity to thymalfasin or excipientsAllergyHigh
- Autoimmune diseases (active)ImmunologicalModerate
- Severe autoimmune diseaseImmunologicalModerate
- Organ transplant recipients on immunosuppressive therapyImmunologicalModerate
- Known hypersensitivity to thymalfasinAllergyHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalUncommon
- Hypersensitivity / allergic reactionsImmunologicRare
- Flu‑like symptomsSystemicUncommon
- Injection site reactionsLocalCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralUncommonLow energy or tiredness
- Transient lymphopeniaHematologicRare
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, cyclosporine, tacrolimus)Moderate
- CyclosporineModerate
- CorticosteroidsModerate
- Interferon-alphaLow
- Vaccines (influenza, hepatitis B)Low
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- LactationReproductiveRelative
- Pediatrics (<2 y)AgeRelative
- Elderly patientsAgeRelative
Regulatory Status
- CNApprovedApproved: immune deficiency, viral hepatitisApproved by NMPA.
- European UnionUnapprovedNo marketing authorization in EU member states.
- JPApprovedApproved: chronic hepatitis B, hepatocellular carcinoma adjunctMarketed as Zadaxin.
- United StatesInvestigationalInvestigational New Drug (IND) status; not FDA‑approved.
- United KingdomUnknownNo MHRA full marketing authorization; may be available via named-patient or special import schemes.
Approved for clinical use in Japan, China, and several other Asian markets; not approved by the US FDA (investigational) and not marketed in the EU.
Evidence & Sources
- Journal ArticleModerateSjogren MH2004-01-01T00:00:00.000000Z
- Journal ArticleModerateQiu SJ, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleModerateSjogren MH2004-01-01T00:00:00.000000Z
- Journal ArticleModerateNiu W, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateCiancio A, Rizzetto M2010-01-01T00:00:00.000000Z
- Journal ArticleModerateXu H, et al.2026-01-01T00:00:00.000000Z
Frequently Asked Questions
What conditions is thymalfasin currently prescribed for?
Thymalfasin is approved as an immunomodulatory peptide and is used in some countries as an adjuvant for chronic hepatitis B and C, and as a supportive therapy in certain cancers such as hepatocellular carcinoma. Its regulatory status varies by region, and it is not universally approved for all the indications studied.
How does thymalfasin differ from standard antiviral drugs?
Unlike direct‑acting antivirals, thymalfasin does not target the virus itself. It works by enhancing the host’s cellular immune response—promoting Th1 activity, T‑cell maturation, and NK‑cell function—thereby improving the body’s ability to clear infected cells when used alongside antiviral regimens.
What evidence supports its use around cancer surgery?
A randomized trial of 400 colorectal‑cancer patients showed that peri‑operative thymalfasin improved immune indices, reduced infection, lowered recurrence and metastasis rates, and extended disease‑free survival. A phase‑II gastric‑cancer study reported a 30% pathological complete response and favorable nodal downstaging when added to immunochemotherapy.
Are there any common side effects?
The most frequently reported effects are mild injection‑site reactions. In a gastric‑cancer trial, 93% of participants experienced any‑grade adverse events, with 26% experiencing grade ≥ 3 events and 23% having immune‑related events. Monitoring for systemic immune activation is recommended, especially in patients with autoimmune conditions.
What is Thymalfasin?
Thymalfasin (thymosin‑α1) is a synthetic immunomodulatory peptide approved as a prescription drug. Delivered by subcutaneous injection, it is used as an immune‑enhancing adjuvant in chronic viral hepatitis, hepatocellular carcinoma, and selected solid‑tumour settings. The peptide seeks to strengthen Th1‑type cellular immunity, promote T‑cell maturation, and augment antiviral or antitumour responses when combined with standard therapies.
What is Thymalfasin used for?
Thymalfasin is educationally associated with: Chronic Hepatitis C treatment, Support cancer immunotherapy, Chronic Hepatitis B treatment, Sepsis adjunctive therapy, Cancer immunoadjuvant, Immune reconstitution in immunocompromised patients, Enhance antiviral immunity, Treat immunodeficiency, COVID-19 adjunctive treatment. Educational only — not medical advice.
How is Thymalfasin administered?
Recorded routes of administration: Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Thymalfasin?
Reported adverse effects include: Flu-like symptoms, Hypersensitivity / allergic reactions, Flu‑like symptoms, Injection site reactions, Nausea, Fatigue, Transient lymphopenia, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Thymalfasin?
Recorded contraindications: Hypersensitivity to thymalfasin or excipients, Autoimmune diseases (active), Severe autoimmune disease, Organ transplant recipients on immunosuppressive therapy, Known hypersensitivity to thymalfasin. Consult a qualified clinician before use.